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In previous reports a  series  of seven antigenic variants of type A influenza 
virus PR8-S strain has been described (1-3).  Each new strain was derived by 
passage  in  lungs  of mice  given homologous vaccine.  Although  the  variants 
in this series showed decreasing serological reactions with PR8 antiserum, all 
antisera  produced  by  the  variants  contained varying  amounts  of  antibody 
which reacted with PRS-S virus. Only two of the seven variants, the fifth and 
sixth,  elicited  relatively low  PR8-S  antibody titers.  However,  the  seventh 
variant virus derived from the sixth provoked significantly more PR8 antibody 
(3). 
In an attempt to decrease further the serological  relationship of the PR8-S 
virus  to  its  variant  offspring,  a  polyvalent vaccine  containing PR8-S  virus 
as a constant component, as well as the variant strain was employed for mouse 
immunization. This was done so that a high antibody titer (immune environ- 
ment) to the PR8-S virus, which might serve to suppress selectively the devel- 
opment of variants with PR8-S characteristics, would be present continually. 
With this procedure a second series of four antigenic variants has been produced. 
The comparative serological  characteristics of the seven variants of the first 
series  and  the  four  variants  of  the second series  employing cross-hemagglu- 
tinin-inhibition,  neutralization,  and  antibody  absorption  tests  will  be  pre- 
sented.  The  variants  of  the  second  series  were  also  compared  with  several 
influenza virus A and A p strains. 
Materials  and  Methods 
In the development of this second series of influenza virus PR8-S variants mice immu- 
nized with monovalent  (PR8-S virus) and polyvalent  (variant virus plus PR8-S) vaccines 
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and  mice  recovered  from  active  PR8-S  virus  infections were  employed.  The  reasons  for 
use of these procedures will be given in the results section. 
The monovalent PR8-S  vaccine was prepared in the manner described in detail in the 
previous paper  (3). The polyvalent vaccines were prepared from dialyzed  first passage in- 
fected allantoic fluid.  One part  PR8-S  fluid was  added  to  nine parts of the variant virus 
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fluenza PRS-S virus variants. 
fluid.  Each virus suspension had approximately the same HA  units per ml. After mixing, 
the vaccine was inactivated by the addition of formalin  (1:4000 dilution) followed by in- 
cubation at 37°C.  for 2 hours. Because of the progressive and marked decline in antigeuicity 
of each new emerging variant, it was necessary to concentrate the variant virus component 
in the vaccines in order to provoke suitable antibody titers for comparative tests. This was 
done by centrifugation of dialyzed infected allantoic fluid in a  Spinco model L  centrifuge 
at 59,000 g for 40 minutes. The pellets then were resuspended in one-tenth the original vol- 
ume of buffered saline. Nine parts of the concentrated variant virus suspension were mixed 
with one part of unconcentrated PR8-S fluid after which the vaccine was inactivated with 
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The  technique of passage, criteria for recognition of a new variant,  the hemagglutinin 
inhibition (H.I.),  in  ovo neutralization, and antibody absorption tests are  similar to those 
outlined in  detail  in  the  previous report  (3). 
RESULTS 
The relationship  of the first and second series of influenza PR8-S variants 
is shown in Fig. 1. The second series was started by passage of the third variant 
(Cb) of the first series in the lungs of mice immunized with PR8-S  vaccine by 
intraperitoneal  inoculation  of  three  0.5  ml.  doses  at  weekly intervals.  After 
32  passages in  the  lungs  of mice with  high  PR8-S  antibody  titer,  the  last 
passage still  elicited  considerable  PR8-S  antibody.  Therefore,  thirteen  addi- 
tional lung passages were made in recovered mice which previously had been 
infected with  the PR8-S virus by the aerosol technique  (4).  Such mice when 
used for passage had H.I. and neutralizing antibody titers ranging respectively 
TABLE I 
Derivation  of Second  Series  of Variants  o] Influenza  PR8-S  Virus in  Mice Immunized  with 
Polyvalent  Vaccines 
Virus inoculated 
intranasally 
Cb* 
D/s 
Fd/s 
Gf/s 
Viruses used for 
immunization of mice 
PR8-S 
D/s and PR8-S 
Fd/s and PR8-S 
Gf/s and PR8-S 
No. of passages in 
immunized mice 
45 
20 
25 
33 
Variant isolated 
D/s 
Fd/s 
Gf/s 
Hg/s 
* Third variant of the first PR8-S series (1-3). 
from 240 to 960 and 200 to 400. After a total of 45 lung passages no significant 
antigenic changes had  occurred.  The passages were then  terminated and the 
variant was designated D/s  (Fig.  1, Table I). 
The  next  three  variants,  Fd/s,  Gf/s,  and  Hg/s,  were  derived  from  lung 
passage in mice given polyvalent vaccine.  The symbols  and  number  of pas- 
sages employed in the serological procedures are given in Table I. As the var- 
iant  components  in  the  vaccines  became  progressively  poorer  antibody 
producers  (5)  the  mice  through  which  the  passages  were  made  had  to  be 
given  from  one  to  three  0.5  ml.  intraperitoneal  inoculations  of  vaccine  at 
weekly  intervals  to  produce  the  desired  antibody  level.  The  antibody  titer 
in such mice varied from 80 to 240. 
Serological  Characteristics  of the  Second  Serics.--The  results of the  eross-H.I,  and  neu- 
tralization tests with those of the first and second series of variants are shown respectively 
in Tables II and III. As in the previous report (3) titer ratios were also employed to make 
the  serological results with  the  different virus variants  more comparable. It can be seen 
that the first variants D/s of the second series showed essentially the same cross-reactions 
as did its predecessor (Cb). The following three variants, however, Fd/s,  Gf/s, and Hg/s, Test viruses  First series 
First series 
PR8-S 
As 
Ba 
Cb 
Dc 
Fd 
Gf 
Hg 
Second series 
Cb 
D/s 
Fd/s 
Gf/s 
Hg/s 
Ferret antisera* 
Cb  PRS-S  As  Ba 
1536  768  768 
256  768  768 
48  192  1024 
32  24  512 
48  128  768 
8  <8  128 
<8  8  128 
8  16  192 
32  24  512 
16  24  512 
<8  <8  64 
<8  <8  32 
<8  <8  16 
100 
384 
192 
256 
768 
192 
384 
384 
128 
768 
512 
96 
32 
8 
Second series 
Dc  Fd  Gf  ] Hg  D/s 
256  96  128  256  256 
384  96  64  128  384 
384  96  128  128  384 
96  512  384  256  512 
$84  96  96  128  256 
32  768  512  128  192 
32  384  519. 128  256 
96  64  128  884  128 
96  512  384  256  512 
64  512  384  128  612 
24  192  96  128  128 
24  24  24  12  64 
8  L<8  16  48  32  1 
Fd/s  Gf/s  Hg/s 
32  16  48 
48  48  16 
32  48  16 
96  48  48 
24]  48  32 
3248  <8 
32  I 24  24 
321  24  32 
I 
96  48  48 
48  24  24 
19'2  48  96 
96  192  96 
481  64  128 
First series 
PR8-S 
As 
Ba 
Cb 
Dc 
Fd 
Gf 
Hg 
Second series 
Cb 
D/s 
Fd/s 
Gf/s 
Hg/s 
66  12 
Titer ratios 
I 
100  75  25  66  50  265  8  37 
25  12 
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TABLE II 
Cross--Hemagglutinin-Inhibition  Tests  with Influenza PR8-S  Virus  and  Its  Variants  of the 
First and Second Series 
17 
3 
2 
3 
<1 
<1 
<1 
2 
1 
<1 
<1 
<1 
100 
25 
3 
16 
<1 
1 
2 
3 
3 
<1 
<1 
<1 
50 
75  25 
100  33 
50  120  ~ 
75 
12  50 
12  50 
18  16 
50  100 
50  66 
6  12 
3  4 
1  1 
.00  12  12 
O0  12  25 
25  66  75 
.00  12  18 
8  00  100 
8  50  12~ 
25  8 
25  75  66 
16  66  75] 
6  2~  18 
6  4 
2  ~1  3 
33  75 
33  75  16  25  12 
66  100  50  I 25  37 
33  2550  12  25  25 
33  38  16  25  <6 
33  50  16  12  18 
.00  16  12  25 
21~  50  25  37 
66  100 
33  100  25  12  18 
33  100  25  75 
3  50  100  75 
12  6  I  25  I  33  1100 
* Reciprocal of the initial serum dilution partially (-4-) inhibiting 4 hemagglutinating units 
of virus. 
Heterologous titer 
Homologous titer  X  100. TABLE III 
Cross-Neutralisation  Tests  with  Influenza  PRS-S  Virus  and  Its  Variants  of the  First  and 
Second Series 
Test viruses 
Ferret  antisera* 
First series 
PR8-S 
As 
Ba 
Cb 
Dc 
Fd 
Gf 
Hg 
Second series 
Cb 
D/s 
Fd/s 
Gf/s 
Ug/s 
'd  P  Gf  Hg 
First  series  Second series 
As 
__  m 
360 
~00 
20 
<8 
40 
5 
6 
8 
<8 
5 
<8 
<8 
<8 
DOROTHY ~,  CLAYTON G.  LOOSLI, AND PAUL GERBER  849 
Hg,/s 
11 
(8:  11 
<8 
~8,  ll 
<8 
<16 
1~  <8 
~8  <8 
22 
50 
81]  130 
'liter ratios~ 
First series 
PR8-S 
As 
Ba 
Cb 
Dc 
Fd 
Gf 
Hg 
Second series 
Cb 
D/s 
Fd/s 
GUs 
Hg/s 
100 
3 
<1 
<i 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
90 
100 
5 
<2 
10 
1 
1 
2 
<2 
1 
<2 
<2 
<2 
85 
85 
00 
6 
51 
6 
3 
9 
6 
30 
3 
3 
3 
50i  1 
12si 
5 
I;  '! 
111  61 
14  33 
33 
14  21 
71  67 
4  26 
O0  O0 
65  00 
18  33] 
I 
71  671 
82  52J 
29  331 
7  231 
8  33] 
89 
~1001 
27  27 
44  55 
27  27 
100  35 
49  100 
<17  11001 
24 
13  11~ 
24 
27i  4 
tTJ  6 
121  8 
11 
4 
11 
12 
22 
11 
8 
35 
50 
6  8 
<9  8 
<9  10 
12  <6 
<9  8 
<9  8 
<9  <6 
<18,<12 
12  <6 
<9  <6 
23  17 
190  ~  38 
100 
* Reciprocal of initial serum dilution preventing infection 
mixed with 1000 EIDso of virus. 
Heterologous titer 
Homologous titer  X  100. 
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F~G. 2. Cross-absorption tests with Cb and its three variant antisera each absorbed with 
PR8-S  and  the  preceding and  succeeding variants. 
showed considerable deviation from the PR8-S virus,  the variants of the first series, and 
the D/s virus. They all failed to react with PR8-S and As antisera and produced only small 
amounts of antibody which reacted with the PR8-S, the variants of the first series and the 
D/s variant of the second series.  Although the results of the H.I. and neutralization tests 
suggest that the last three variants of the second series are quite similar, cross-absorption DOROTHY  HAMRE~  CLAYTON  0. LOOSLI~  AND PAUL GERBEE  851 
tests of these antisera with the PR8-S virus and  preceding and  succeeding variant viruses 
revealed individual  antigenic  characteristics. 
A,tibody  Absorption Tests.--The  results  of  the  cross-absorption  tests  with  the  PR8-S 
vires and the viruses and antisera of the second series,  are shown in Figs. 2 and 3. All ho- 
mologous absorptions  removed all antibody  and  are  omitted  from  the  figures.  It  can  be 
seen in Fig. 2  that  absorption  of Cb,  D/s,  Fd/s,  and  Gf/s antisera with PR8-S  removed 
all its antibody but left varying amounts which reacted with Cb and the respective Bar-S 
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FIG. 3.  Cross-absorption of Gf/s and Hg/s antisera with respective antigens and  PR8-S 
VH'US. 
variants.  Cb  and  D/s antisera  showed complete cross-absorption  by the respective heter- 
ologous virus which confirms their close antigenic relationship suggested by the results with 
cross-H.I,  and  neutralization tests  (Tables II and  III).  The antibodies in Fd/s antiserum 
after absorption with PR8-S virus showed a  shift in proportions,  that is, less titer was left 
to Cb and  D/s viruses, a  high titer to homologous virus remained,  and  the titer  to Gf/s 
virus was  unchanged.  This  trend  continued  in  the  results  obtained  with  Gf/s antiserum 
absorbed  with PR8-S virus, but in this case the titer with Fd/s virus was lower than  the 
homologous titer. 
Cross-absorption  tests between D/s and  Fd/s indicated  that  Fd/s virus had  lost com- 
ponents present in D/s since absorption of D/s antiserum with Fd/s virus did not remove 
all antibody but left components which reacted with PR8-S, Cb, and  D/s. However, Fd/s 852  ANTIGENIC  VARIANTS  O]~ INFLUENZA  A  VIRUS.  IV 
virus acquired a  new antigen because absorption of Fd/s antiserum with D/s virus left es- 
sentially all the Fd/s antibody. After absorption  of Fd/s antiserum with Gf/s a  high titer 
to Fd/s virus also remained.  Absorption  of Gf/s antiserum with Fd/s virus, however, re- 
moved all except a low titer to Gf/s virus. If these results are examined along with the titers 
left in these two  (Fd/s and  Gf/s)  antisera  after absorption  with PRS-S virus,  it appears 
TABLE IV 
H. I. Antibody Tiler Ratios of Antisera of Variants of the Second Series  Tested with Swine and 
Type A  and A ' lnfluenza  Viruses 
Test viruses  Date isolated 
Swine 
Type A 
WS 
PRS-S 
Mel 
BH 
Gatenby 
Talmey 
Alaska 
Bloom 
Gideon 
Hickcox 
Dyken 
Hemsbury 
DSP 
Weiss 
Type A I 
Cam 
FM1 
Sweden 
Boch 
Wright 
Malaya 
Alb/1 
aa/4 
Ned/36 
Denver/1 
GL/10 
1931 
1933 
1934 
1935 
1935 
1937 
1937 
1937 
1937 
1940 
1940 
1941 
1943 
1943 
1943 
1946 
1947 
1950 
1951 
1953 
1954 
1955 
1956 
1956 
1957 
1957 
PR8-S 
<1 
<i 
100 
25 
1 
3 
12 
25 
67 
17 
<1 
50 
25 
<1 
25 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
<1 
"liter ratios of ferret antisera 
D/s 
<8 
12 
50 
17 
4 
<8 
4 
25 
33 
8 
<4 
12 
4 
<4 
12 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
Fd/s 
12 
12 
25 
17 
8 
<8 
25 
8 
25 
33 
<8 
8 
<8 
<8 
<8 
<12 
19 
<12 
<12 
<12 
<12 
<4 
<4 
<4 
<4 
<4 
GUs 
<8 
8 
i  <s 
i  8 
<8 
16 
8 
8 
12 
<8 
i  <8 
<8 
<8 
<8 
<8 
18 
<8 
<8 
<8 
<8 
i  <12 
I  <12  i 
<12 
<12 
<12 
Hg/s 
<12 
<12 
37 
<12 
<12 
<12 
12 
12 
12 
50 
<12 
25 
<12 
<12 
<12 
<8 
12 
<8 
<8 
<8 
<8 
<6 
<6 
<6 
<6 
<6 
likely that Fd/s contains the antigen which becomes dominant in Gf/s. Thus after PR8-S 
absorption of Fd/s antiserum,  the Fd/s titer is higher than the Gf/s titer, and the reverse 
is true for Gf/s antiserum  (Fig. 2). 
The results after absorption of Gf/s and Hg/s antisera with the respective heterologous 
antigens and PRS-S virus are shown in Fig. 3. It can be seen that similar antibody patterns 
remained after absorption  of these antisera with  the PR8-S virus. The absorption  of Gf/s 
antiserum  with Hg/s virus left only a  low antibody  fiter to  Gf/s antigen;  however, after 
absorption of Hg/s antiserum with Gf/s antigen a high titer to the homologous (Hg/s) virus 
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The results of the absorption tests indicate that variants Fd/s,  Gf/s, and Hg/s of the 
second series are characterized by a  decrease in antigenic components present in the parent 
Cb and the D/s viruses and the appearance of new components which are shared in vary- 
ing degrees themselves. In additional experiments not given in table or graph form it was 
shown that these new components in the absorbed Fd/s,  Gf/s, and Hg/s antisera did not 
react with the Cb and Dc variants of the first series of PR8 variants. Likewise, none of the 
variants of the second series, when used  to absorb PRS-S  antiserum, significantly reduced 
the antibody titer. This confirmed the lack of cross-reaction in the H.I.  and neutralization 
tests between PRS-S  antiserum and  these viruses. 
Serological Comparison of Variants of the Second Series with Other Influenza  Type A  and 
A' Struins.--In cross-H.I, tests none of the variant viruses reacted with any of the antisera 
of swine, fourteen strains of type A and eleven strains of A ~ influenza virus. However, when 
the antisera of  these variants were tested with the variant viruses certain reactions were 
observed. The results are expressed in antibody titer ratios and presented in Table IV. Anti- 
sera of Fd/s and Gf/s variants showed low H.I.  antibody titers with the swine virus. This 
is notable only because none of the variants of the first series (3) or the rest of the variants 
in the second series showed any reaction with this antigen. 
In  Table  IV  it  can  be  seen  that  generally  there  was  less  reaction  between  the 
type A  strains and the variants succeeding D/s than had been obtained with seven vari- 
ants of the first series (3). The lower homologous titers of Fd/s,  Gf/s, and Hg/s compared 
to those of the other variants may be responsible for this. It is interesting to note that D/s, 
which was shown by cross-absorption tests to be very closely related to Cb variant of the 
original line, did  not  show  a  titer  ratio  with  Cam,  Wright,  or  AA/4  as  had Cb antise- 
rum  (3). 
Among the A' strains, only FMI reacted with Fd/s,  Gf/s, and Hg/s anfisera. The  titer 
ratios were low, 12 to 19. No reactions, however, were observed in cross-neutralization tests 
with these antisera and FM1  virus. This is similar to the reaction between Cb antiserum 
of  the first  series and  Cam  and  Wright viruses  (3). 
DISCUSSION 
Experiments reported in this and the previous paper (3) have demonstrated 
that influenza virus type A, PR8 strain, will alter antigenically when grown 
in the presence of homologous antibody in mice. This has provided a labora- 
tory model for study of antigenic variation of this virus, which has been well 
documented in the epidemiology  of the disease  in man (5-7).  In two series 
of passages  in immunized mice; one, in which each variant was derived from 
the preceding  one,  and the second, in which each variant was derived from 
the preceding  one, but in the presence  of a  continuous antibody titer to the 
original virus PR8, the antigenic composition of the variants differed markedly. 
Not only did the variants in these two series contain different "new" antigens, 
but also two variants in the second series had less PR8 component than any 
of the variants in the first series. This lends  support to the hypothesis that 
the maintenance of antibody levels to PR8 virus in mice will lead to reduction 
of  the  PR8  component  in  the  emerging  variants.  However,  while  recog- 
nizing the importance of the immune state of the host, the precise mechanism 
in the selection of a new major antigenic  component in the emerging variant 
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sary to determine whether or not  this  selection is  a  random or a  regulated 
one. Such studies are now in progress. 
As with the first series of PR8-S variants  (3) cross-H.I, tests with several 
type A and A' strains of influenza virus and the variants of the second series 
failed  to  reveal  any  close  relationships.  The  only  cross-reactions  were  ob- 
tained with antisera of the variants and some of the type A  and A' viruses. 
Lack of cross-reactions with antisera of the type A and A r viruses presumably 
indicates that none of the variants share with them major common antigens. 
Further  evidence  that  the  serological  deviations  noted  in  the  two  series 
of PR8-S  variants  represent  a  major  change  in  antigenicity is  revealed in 
the cross-protection tests.  The results of these tests along with  those which 
measure virulence, antigenicity, and immunogenicity will be presented in the 
following paper (8). 
SUx~rARY 
A second series of four variants of PR8-S virus has been produced by pas- 
sage  of  the  variants in the lungs of mice immunized with the PR8-S  virus 
as well as the homologous strain. The PR8-S virus was added as a  constant 
component of the vaccine so that a  high antibody titer to it would suppress 
selectively the development of variants with PR8-S characteristics. Compara- 
tive H.I.  and  in  ovo  neutralization  tests  with  the  first and  second series of 
variants revealed that the three variants, Fd/s, Gf/s, and Hg/s, of the second 
series, failed to react with PR8-S antisera and produced significantly smaller 
amounts  of  antibody  which  reacted  with  PR8-S,  the  variants  of  the  first 
series,  and the first variant  (D/s)  of the second series. Although these three 
variants  reacted  quite  similarly  in  the  H.I.  and  neutralization  tests  cross- 
absorption of these sera with the PR8-S virus and themselves revealed indi- 
vidual antigenic characteristics. While these studies emphasize the importance 
of the immune state of the host the precise mechanism in the selection of a 
new  antigenic component in the emerging variant must yet be determined. 
BIBLIOGRAPHY 
1.  Gerber, P., Loosli, C.  G.,  and Hamre, D., Antigenic  variants of influenza virus 
(PR8 strain). I. Their development during serial passage  in the lungs  of par- 
tially immune  mice, J. Exp. Med.,  1955, 101, 627. 
2.  Gerber, P., Hamre, D., and Loosli, C. G., Antigenic variants of influenza A virus 
(PR8  strain).  II.  Serological  and  immunological  characteristics  of  variants 
derived from variants., J. Exp. Meal., 1956, 103, 413. 
3.  Hamre, D., Loosli, C. G., and Gerber, P., Antigenic variants of influenza A virus 
(PR8  strain).  III.  Serological relationships  of  a  line  of variants  derived  in 
sequence in  mice given  homologous vaccine,  J. Exp. Med.,  1958, 107, 829. 
4.  Loosli, C. G., Robertson, O. H., and Puck, T. T., The production of experimen- DOROTttYHAMRE~ CLAYTON G. LOOSe, AND PAUL GERBER  855 
tal  influenza  in  mice by  inhalation  of atmospheres containing  influenza  virus 
dispersed  as  fine droplets,  J.  Infect.  Dis.,  1943, 72,  142. 
5.  Magill,  T.  P.,  and  Francis,  T.,  Jr.,  Antigenic  differences  in  strains  of epidemic 
influenza virus. I.  Cross-neutralization  tests in mice, Brit. J. Exp. Path., 1938, 
19, 273. 
6.  Smith,  W.,  and  Andrewes,  C.  H.,  Serological  races  of  influenza  virus,  Brit.  J. 
Exp. Path., 1938, 19, 293. 
7.  Van der Veen, J., and Mulder, J., Studies on the Antigenic Composition of Human 
Influenza Virus  A  Strains,  Leiden,  Stenfert  Kroese,  1950. 
8.  Loosli, C. G., Hamre, D., and  Gerber, P., Antigenic variants of influenza A virus 
(PR8  strain).  V.  Virulence,  antigenic  potency,  and  cross  protection  tests  in 
mice of the original and  second  series, J. Exp. Med.,  1958, 107, 857. 